3 December 2025 (Wednesday) - NEQAS 2507 BF

I got hold of the results of NEQAS 2507 BF today…

 

2507BF1

 

I wrote

 

Hypochromic (consensus 1^st)

Microcytic      (consensus 3^rd)

Pencil cells    (consensus 4^th)

Target cells   (consensus 2^nd)

Tear drop cells (consensus 6^th)

 

I wrote ?? Fe def. The expert opinion said “2507BF1 was the blood film from a 23-year-old woman with iron deficiency anaemia,”

 

 

25007BF2

 

Macrocytosis (consensus 4^th)

HJB

Tear drop cells (consensus 6^th)

Hypersegmented neut (consensus 1^st)

Low plts (consensus 3^rd)

 

I wrote ?? B12 def The expert opinion said “2507BF2 was the blood film from a 56-year-old man with nutritional megaloblastic anaemia”

 

I’ll take that…

 

3 December 2025 (Wednesday) - NEQAS 2504 PA

I got hold of the results of NEQAS 2504 PA today…

2504 PA1

This was “the thin blood film from a patient of unspecified age and sex and with an unknown travel history. It showed a heavy (2.1%) infestation with Plasmodium knowlesi malaria”.  

I wrote “P falciparum - rings, trophozoites & shizonts 5% parasitaemia”. I got the species wrong and overestimated the parasitaemia, but I spotted malaria.

2504 PA2

The expert opinion said “There were no parasites to see on this thick film” 

I wrote “Think it's negative. Saw one iffy thing”

 

I’ll take that…

3 December 2025 (Wednesday) - Westgard QC Update

The nice people at Wesgard QC sent out their newsletter today. You can read it by clicking here. Much of it was rather dry; much of it went over my head. But one article gave me a wry smile. A bit of a diatribe about how people are using QC terms to blag their way, safe in the knowledge that no one knows what they are talking about.

 

I’m not the only one who finds QC matters rather esoteric.

2 December 2025 (Tuesday) - Mild Neutropenia

People can be very quick to get incredibly over-excited about mild neutropenia. It can have several causes which don’t require massive over-reaction. Here’s one such:

2 December 2025 (Tuesday) - Fritsma Factor Newsletter

The Fritsma Factor newsletter appeared in my in-box today. You can see it by clicking here. This month there was quite a bit more than there usually is, Underfilled samples, anticoagulation, the PT, haemophilia…

Loads of stuff.

 

2 December 2025 (Tuesday) - Exchange Transfusions

There’s a phrase that is in common use – “exchange transfusion”. It implies that you take out all of someone’s blood because it is in some way sub-standard and exchange it for “decent” stuff. But you can’t just hoik it all out before putting in the good stuff as that would be fatal. Similarly putting the good stuff in one arm whilst taking out the bad from the other will lead to a degree of mixing.

Here’s an article examining the logistics of how it might best be done…

1 December 2025 (Monday) - BTLP-TACT Exercise

Last month I did thirteen BTLP-TACT cases, and still I’m getting emails about not doing enough… so here we go.

I was presented with one case – an eleven year old girl in ITU with burns needing two units of blood.

 

She grouped as A Rh(D) Positive with a negative antibody screen. I selected two units of A Rh(D) Positive K-Negative blood

 

I got the thumbs-up.

1 December 2025 (Monday) - Learning Monday

I won’t lie. I don’t know. It’s AML. Back in the day we’d do a Sudan Black stain and that was good enough.  Things have massively changed in the understanding and diagnosis of leukaemia.

 

Here’s the answer:

 

“Correct answers are A and B. This case illustrates a discrepancy between the two AML classification systems and underscores the complexity of diagnosis in the presence of multiple genetic alterations. An integrated diagnostic approach, including flow cytometry, cytogenetics, and molecular genetics, is necessary to reach a final diagnosis. The patient would be classified as an AML with mutated TP53 according to ICC 2022 and as an AML myelodysplasia-related according to WHO 2022. In the ICC 2022 classification, AML with mutated TP53 is recognized as a separate entity, including Pure Erythroid Leukemia, if morphologic criteria for this entity are respected.  According to WHO 2022, 5q deletion is included in the cytogenetic abnormalities defining AML-MR.  In both systems, the diagnosis of AEL (WHO 2022) or PEL (ICC 2022) requires ≥30% immature erythroid cells (proerythroblasts) and a bone marrow with erythroid predominance (≥80% of cellularity). The case of this patient doesn't comply with the criteria of the >30% proerythroblasts (he does have 45% of erythropoiesis in the BM, but not 30% or proerythroblasts)”.

 

Here’s a link to an article on the matter from an expert panel. I’ll make the observation that it wasn’t that long ago that we were all far more knowledgeable on the matter as we used to do a lot of the testing in-house and not send it off to reference labs…